Trial Profile
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 µg Bid) and Doses of Open Label Sandostatin (SMS) (100 µg Tid) in Acromegalic Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Oct 2014 New trial record